Perrigo Company plc PRGO
The next Perrigo Company plc dividend is expected to go ex in 1 month and to be paid in 2 months.
The previous Perrigo Company plc dividend was 22.5c and it went ex 2 months ago and it was paid 1 month ago.
There are typically 4 dividends per year (excluding specials), and the dividend cover is approximately 5.1.
|Summary||Previous dividend||Next dividend|
|Per share||22.5c||Sign Up Required|
|Declaration date||22 Oct 2020 (Thu)||16 Feb 2021 (Tue)|
|Ex-div date||25 Nov 2020 (Wed)||25 Feb 2021 (Thu)|
|Pay date||15 Dec 2020 (Tue)||16 Mar 2021 (Tue)|
Enter the number of Perrigo Company plc shares you hold and we'll calculate your dividend payments:
Sign up for Perrigo Company plc and we'll email you the dividend information when they declare.
Add Perrigo Company plc to receive free notifications when they declare their dividends.
Your account is set up to receive Perrigo Company plc notifications.
|Status||Type||Decl. date||Ex-div date||Pay date||Decl. Currency||Forecast amount||Decl. amount||Accuracy|
|Forecast||Quarterly||23 Jul 2025||28 Aug 2025||15 Sep 2025||USD||Sign up||—|
|Forecast||Quarterly||29 Apr 2025||29 May 2025||17 Jun 2025||USD||Sign up||—|
|Forecast||Quarterly||11 Feb 2025||27 Feb 2025||18 Mar 2025||USD||Sign up||—|
|Forecast||Quarterly||17 Oct 2024||28 Nov 2024||17 Dec 2024||USD||Sign up||—|
|Forecast||Quarterly||24 Jul 2024||29 Aug 2024||16 Sep 2024||USD||Sign up||—|
|Forecast||Quarterly||30 Apr 2024||30 May 2024||18 Jun 2024||USD||Sign up||—|
|Forecast||Quarterly||13 Feb 2024||29 Feb 2024||19 Mar 2024||USD||Sign up||—|
|Forecast||Quarterly||19 Oct 2023||30 Nov 2023||19 Dec 2023||USD||Sign up||—|
|Forecast||Quarterly||26 Jul 2023||24 Aug 2023||12 Sep 2023||USD||Sign up||—|
|Forecast||Quarterly||02 May 2023||25 May 2023||13 Jun 2023||USD||Sign up||—|
|Forecast||Quarterly||14 Feb 2023||02 Mar 2023||21 Mar 2023||USD||Sign up||—|
|Forecast||Quarterly||20 Oct 2022||23 Nov 2022||13 Dec 2022||USD||Sign up||—|
|Forecast||Quarterly||27 Jul 2022||25 Aug 2022||13 Sep 2022||USD||Sign up||—|
|Forecast||Quarterly||03 May 2022||26 May 2022||14 Jun 2022||USD||Sign up||—|
|Forecast||Quarterly||15 Feb 2022||24 Feb 2022||15 Mar 2022||USD||Sign up||—|
|Forecast||Quarterly||21 Oct 2021||24 Nov 2021||14 Dec 2021||USD||Sign up||—|
|Forecast||Quarterly||28 Jul 2021||26 Aug 2021||14 Sep 2021||USD||Sign up||—|
|Forecast||Quarterly||04 May 2021||27 May 2021||15 Jun 2021||USD||Sign up||—|
|Forecast||Quarterly||16 Feb 2021||25 Feb 2021||16 Mar 2021||USD||Sign up||—|
|Paid||Quarterly||22 Oct 2020||25 Nov 2020||15 Dec 2020||USD||23c||22.5c||😃|
|Paid||Quarterly||29 Jul 2020||27 Aug 2020||15 Sep 2020||USD||23.5c||22.5c||😃|
|Paid||Quarterly||05 May 2020||28 May 2020||16 Jun 2020||USD||24c||22.5c||😊|
|Paid||Quarterly||18 Feb 2020||27 Feb 2020||17 Mar 2020||USD||21c||22.5c||😊|
|Paid||Quarterly||04 Nov 2019||27 Nov 2019||17 Dec 2019||USD||21c||21c||😄|
|Paid||Quarterly||31 Jul 2019||29 Aug 2019||17 Sep 2019||USD||—||21c|
|Paid||Quarterly||26 Apr 2019||30 May 2019||18 Jun 2019||USD||—||21c|
|Paid||Quarterly||14 Feb 2019||28 Feb 2019||19 Mar 2019||USD||—||19c|
|Paid||Quarterly||31 Oct 2018||29 Nov 2018||18 Dec 2018||USD||—||19c|
|Paid||Quarterly||01 Aug 2018||30 Aug 2018||18 Sep 2018||USD||—||19c|
|Paid||Quarterly||03 May 2018||31 May 2018||19 Jun 2018||USD||—||19c|
|Paid||Quarterly||15 Feb 2018||01 Mar 2018||20 Mar 2018||USD||—||19c|
|Paid||Quarterly||02 Nov 2017||30 Nov 2017||19 Dec 2017||USD||—||16c|
|Paid||Quarterly||08 Aug 2017||23 Aug 2017||12 Sep 2017||USD||—||16c|
|Paid||Quarterly||03 May 2017||24 May 2017||13 Jun 2017||USD||—||16c|
|Paid||Quarterly||21 Feb 2017||01 Mar 2017||21 Mar 2017||USD||—||16c|
|Paid||Quarterly||08 Nov 2016||22 Nov 2016||13 Dec 2016||USD||—||14.5c|
|Paid||Quarterly||02 Aug 2016||24 Aug 2016||13 Sep 2016||USD||—||14.5c|
|Paid||Quarterly||26 Apr 2016||25 May 2016||14 Jun 2016||USD||—||14.5c|
|Paid||Quarterly||06 Feb 2016||24 Feb 2016||15 Mar 2016||USD||—||14.5c|
|Paid||Quarterly||04 Nov 2015||24 Nov 2015||15 Dec 2015||USD||—||12.5c|
|Paid||Quarterly||12 Aug 2015||26 Aug 2015||15 Sep 2015||USD||—||12.5c|
|Paid||Quarterly||28 Apr 2015||27 May 2015||16 Jun 2015||USD||—||12.5c|
|Paid||Quarterly||27 Jan 2015||25 Feb 2015||17 Mar 2015||USD||—||12.5c|
|Paid||Quarterly||03 Nov 2014||25 Nov 2014||16 Dec 2014||USD||—||10.5c|
|Paid||Quarterly||13 Aug 2014||27 Aug 2014||16 Sep 2014||USD||—||10.5c|
|Paid||Quarterly||28 Apr 2014||28 May 2014||17 Jun 2014||USD||—||10.5c|
|Paid||Quarterly||29 Jan 2014||26 Feb 2014||18 Mar 2014||USD||—||10.5c|
|Paid||Special||07 Dec 2013||19 Dec 2013||–||USD||—||1c|
|Paid||Quarterly||06 Nov 2013||26 Nov 2013||17 Dec 2013||USD||—||9c|
|Paid||Quarterly||14 Aug 2013||28 Aug 2013||17 Sep 2013||USD||—||9c|
|Paid||Quarterly||02 May 2013||30 May 2013||–||USD||—||9c|
|Paid||Quarterly||31 Jan 2013||28 Feb 2013||–||USD||—||9c|
|Paid||Quarterly||06 Nov 2012||28 Nov 2012||–||USD||—||9c|
|Paid||Quarterly||–||30 Aug 2012||–||USD||—||8c|
|Paid||Quarterly||–||31 May 2012||–||USD||—||8c|
|Paid||Quarterly||–||01 Mar 2012||–||USD||—||8c|
|2021||Sign Up Required|
|2022||Sign Up Required|
|2023||Sign Up Required|
|2024||Sign Up Required|
|2025||Sign Up Required|
Perrigo Company plc Optimized Dividend Chart
About Perrigo Company plc
Perrigo Company PLC (Perrigo), formerly Perrigo Company Limited, incorporated on June 28, 2013, is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company. The Company's segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx) and Specialty Sciences. The Company manufactures OTC healthcare products and supplies infant formulas for the store brand market. It is also a provider of generic extended topical prescription products. It provides healthcare products across a range of product categories and geographies, primarily in North America, Europe and Australia, as well as in other markets, including Israel and China.
The Company's CHC segment is focused on the sale of OTC store brand products, including cough, cold, allergy and sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food and diagnostic products. The Company markets in various geographies, including the United States, the United Kingdom and Mexico. Its branded products include the Good Sense, Sergeant's, Sentry, Herron, PetArmor value brands, and the ScarAway brand name.
Branded Consumer Healthcare
The Company's BCH segment develops, manufactures, markets and distributes various European OTC brands in categories, such as natural health, cough, cold and allergy, personal care and derma-therapeutics, lifestyle and pain relief. In addition, the segment manages its regulatory, sales and distribution infrastructure to in-license, and sells non-owned brands and generic pharmaceutical products.
The Company's Rx segment develops, manufactures and markets a portfolio of generic and specialty pharmaceutical prescription drugs for the United States and the United Kingdom markets. It offers a range of topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions and powders. The portfolio also includes select controlled substances, injectables, hormones, women's health products, oral solid dosage forms and oral liquid formulations. Its development areas include other delivery systems, such as oral liquids, metered dose inhalers, injectables and transdermal products. In addition, the Rx segment offers OTC products through the prescription channel (referred to as ORx, these products are marketed using the Perrigo name). ORx products are OTC products that are available for pharmacy fulfillment and healthcare reimbursement when prescribed by a physician. It offers various ORx products that are reimbursable through various health plans and the United States Medicaid and Medicare programs. It manufactures and distributes a range of generic prescription products under various brand names, including Differin, BenzaClin, Entocort, Evoclin, Duac, Olux, Olux-E, Clobex, Desonate, Tridesilon, D.H.E. 45, Ultravate, Bactroban, Mycostatin, Elimite, Klor-Con, Protopic, Androgel, Depo, Testosterone and Triderm/Kenalog.
The Company's Specialty Sciences segment consists of assets focused on the treatment of multiple sclerosis, specifically in connection with the drug, Tysabri (natalizumab). Tysabri also focused on the treatment of Crohn’s diseases.
The Company competes with LNK International, Inc., PL Developments, International Vitamin Corporation, Dr. Reddy's Labs, Johnson & Johnson, Pfizer, Bayer AG, Nestle S.A., Abbott Nutrition, NBTY, Mead Johnson Nutrition Co., Reckitt Benckiser, Boehringer Ingelheim, Novartis, Allergan plc, Apotex Corp., Glenmark Generics Inc., Impax Laboratories, Inc., Mylan N.V., Prasco, LLC, Sandoz, Sun Pharmaceuticals, Taro Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Triax Pharmaceuticals, LLC and Zydus Pharmaceuticals, Inc.
- Pharmaceuticals & Biotechnology
- United States
- Share Price
- $43.29 (yesterday's closing price)
- Shares in Issue
- 136 million
- Market Cap
- Market Indices
- S&P 500